A Study of IBI362 in Participants With Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of
IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects
With Type 2 Diabetes.